Trexquant Investment LP Raises Position in Bausch Health Cos Inc. $BHC

Key Points

• Trexquant Investment LP increased its stake in Bausch Health Cos Inc. by 37.9%, owning approximately 411,440 shares worth $2.66 million after purchasing an additional 113,106 shares.
• Analysts have upgraded Bausch Health from a "hold" to a "buy" rating, reflecting positive sentiment despite a recent earnings report that showed a miss on EPS estimates.
• Director John Paulson significantly increased his ownership by acquiring over 34 million shares, raising his total to approximately 70.8 million shares, representing a 96.35% increase in his stake.

Trexquant Investment LP lifted its position in shares of Bausch Health Cos Inc. (NYSE:BHC - Free Report) by 37.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 411,440 shares of the company's stock after purchasing an additional 113,106 shares during the period. Trexquant Investment LP owned about 0.11% of Bausch Health Cos worth $2,662,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Wells Fargo & Company MN boosted its holdings in shares of Bausch Health Cos by 7.9% during the fourth quarter. Wells Fargo & Company MN now owns 25,907 shares of the company's stock worth $209,000 after purchasing an additional 1,896 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Bausch Health Cos during the fourth quarter worth $180,000. Dimensional Fund Advisors LP boosted its holdings in Bausch Health Cos by 3.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,113,107 shares of the company's stock valued at $25,089,000 after acquiring an additional 90,166 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Bausch Health Cos by 5.7% during the fourth quarter. The Manufacturers Life Insurance Company now owns 260,378 shares of the company's stock valued at $2,108,000 after acquiring an additional 14,042 shares during the period. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Bausch Health Cos in the fourth quarter valued at about $97,000. Institutional investors and hedge funds own 78.65% of the company's stock.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Bausch Health Cos from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Three equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $9.00.

Bausch Health Cos Stock Performance

BHC traded down $0.01 during trading on Monday, hitting $7.34. 526,468 shares of the company traded hands, compared to its average volume of 2,660,863. The firm has a market cap of $2.72 billion, a P/E ratio of 28.25 and a beta of 0.48. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 141.90. The stock's fifty day moving average is $6.84 and its 200 day moving average is $6.09. Bausch Health Cos Inc. has a one year low of $4.25 and a one year high of $9.85.

Bausch Health Cos (NYSE:BHC - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.97 by ($0.07). The company had revenue of $2.57 billion for the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. Bausch Health Cos has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Bausch Health Cos Inc. will post 4.41 EPS for the current fiscal year.

Insider Buying and Selling

In other Bausch Health Cos news, Director John Paulson bought 34,721,118 shares of the business's stock in a transaction that occurred on Thursday, August 14th. The stock was purchased at an average cost of $9.00 per share, with a total value of $312,490,062.00. Following the completion of the acquisition, the director owned 70,755,869 shares in the company, valued at $636,802,821. This trade represents a 96.35% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have purchased 44,316,834 shares of company stock worth $369,628,560. 19.97% of the stock is currently owned by company insiders.

Bausch Health Cos Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.